MRG-002 is under clinical development by Shanghai Miracogen and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MRG-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MRG-002 is under development for the treatment of gastric cancer, HER2-positive metastatic breast cancer, human epidermal growth factor receptor 2 negative breast cancer (HER2- Breast Cancer), advanced or metastatic biliary adenocarcinoma, recurrent or metastatic breast cancer, gastroesophageal (GE) junction carcinomas, advanced or metastatic urothelial carcinoma including bladder cancer, urethral cancer, ureter cancer, salivary gland cancer, esophageal cancer, breast cancer and HER2-expressing advanced malignant solid tumors. It is administered through intravenous route. The drug candidate is an antibody-drug conjugate which is developed by based on ADC technology. The therapeutic candidate acts by targeting HER-2.
It was under development for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC), squamous non-small cell lung carcinoma and Metastatic Biliary Tract Cancer.
Shanghai Miracogen overview
Shanghai Miracogen., biotechnology company that offers development, clinical research and industrialization of new cancer targeted therapy drugs-the world’s cutting-edge technology Antibody Drug Conjugate (ADC) and innovative antibody anti-tumor drugs
For a complete picture of MRG-002’s drug-specific PTSR and LoA scores, buy the report here.